Références utilisées pour le contenu de cette section

1. Alkindi M, Siminovitch KA, Gupta M, Genest J. Monoclonal antibodies for the treatment of hypercholesterolemia: targeting PCSK9. Can J Cardiol 2016;32:1552–60.
2. À propos du syndrome métabolique, MetSC – Metabolic Syndrome Canada, https://www.metabolicsyndromecanada.ca/fr/%C3%A0-propos-du-syndrome-m%C3%A9tabolique
3. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22.
4. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302–9.
5. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston A, Smink RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC; The POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946–955.
6. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670–1681.
7. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD5, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532–2561.
8. Dyslipidémie. Michael Davidson. Manuel Merck pour les professionnels. (2021)
9. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., … & Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European heart journal, 38(32), 2459-2472.
10. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012;60:2631–2639.
11. Ferrieres J, Ruidavets JB, Perret B, Dallongeville J, Arveiler D, Bingham A, Amouyel P, Haas B, Ducimetiere P. Prévalence des dyslipidémies dans un échantillon représentatif de la population française. Archives des maladies du coeur et des vaisseaux. 2005;98(2):127–32
12. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047–56.
13. Le Cholestérol et votre cœur. Institut de cardiologie de l’Université d’Ottawa. (2021)
14. Le Médecin du Québec (2013). Nouvelles lignes directrices sur les lipides : mieux cibler pour mieux traiter, volume 48, numéro 9, septembre 2013
15. Maladies cardiovasculaires.(2017) OMS. https://www.who.int/fr/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
16. Michael Pignone. (2021) Management of elevated low density lipoprotein-cholesterol (LDL-C) in primary prevention of cardiovascular disease. UptoDate, consultation le 27 janvier 2022
17. Pearson GJ et al, Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol 2021
18. Scheidt-Nave C, Du Y, Knopf H, Schienkiewitz A, Ziese T, Nowossadeck E, Gößwald A, Busch MA. Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1) BGG. 2012;56(5 6):325–30.
19. Sidhu D, Naugler C. Fasting time and lipid levels in a community based population: a cross-sectional study. Arch Intern Med 2012;172:1707–10.
20. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337–45.
21. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;339(1):12.
22. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey. J Clin Lipidol. 2012;6(4):325–30.